AtriCure director receives 6,144-share stock grant

AtriCure, Inc. director Kristine B. Johnson reported receiving a grant of common stock as equity compensation.

Rhea-AI Filing Summary

AtriCure, Inc. director Kristine B. Johnson reported receiving a grant of common stock as equity compensation. She acquired 6,144 shares of Common Stock on May 18, 2026 at a stated price of $0.00 per share under the AtriCure, Inc. 2023 Stock Incentive Plan.

The award is structured as a Restricted Stock Award, with all 6,144 shares scheduled to vest on the one-year anniversary of the grant date. Following this grant, Johnson directly holds a total of 55,954 shares of AtriCure common stock, reflecting her updated ownership position as reported.

Insights

Equity Compensation Analyst

Director received a routine restricted stock grant that modestly increases her equity stake.

Director Kristine B. Johnson acquired 6,144 shares of AtriCure common stock via a Restricted Stock Award at a stated price of $0.00 per share. This appears to be standard board compensation granted under the AtriCure, Inc. 2023 Stock Incentive Plan, not an open-market purchase.

The award vests in full on the one-year anniversary of the May 18, 2026 grant date, aligning her incentives with long-term company performance over at least the next year. After this grant, she directly holds 55,954 shares, indicating a meaningful but not unusually large personal stake based on this filing alone.

Insider Trade Summary

Grant/Award: 6,144 shares

Grant/Award 1 txn

Insider JOHNSON B KRISTINE

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,144	$0.00	$0.00

Holdings After Transaction: Common Stock — 55,954 shares (Direct)

Footnotes (1)

1. F1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Key Figures

Restricted stock granted: 6,144 shares Grant price: $0.00 per share Post-grant holdings: 55,954 shares +2 more

5 metrics

Restricted stock granted 6,144 shares Common Stock grant on May 18, 2026

Grant price $0.00 per share Restricted Stock Award under 2023 Stock Incentive Plan

Post-grant holdings 55,954 shares Total AtriCure common stock directly held after transaction

Vesting schedule 1 year Shares vest on one-year anniversary of grant date

Transaction code A Grant, award, or other acquisition of common stock

Key Terms

Restricted Stock Award, AtriCure, Inc. 2023 Stock Incentive Plan, Common Stock, Form 4

4 terms

Restricted Stock Award financial

"The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

A restricted stock award is company shares given to an employee or executive that cannot be sold or fully owned until certain conditions—like staying with the company for a set time or hitting performance targets—are met. Think of it as a gift that only becomes yours after you fulfill specific obligations; for investors, these awards matter because they can increase the total shares outstanding when they vest, reveal how management is being paid and motivated, and create potential selling pressure when restrictions lift.

AtriCure, Inc. 2023 Stock Incentive Plan financial

"pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan."

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AtriCure (ATRC) director Kristine Johnson report in this Form 4?

Director Kristine B. Johnson reported receiving a grant of 6,144 shares of AtriCure common stock. The shares were awarded as a Restricted Stock Award under the 2023 Stock Incentive Plan and are part of her equity-based compensation rather than an open-market stock purchase.

How many AtriCure (ATRC) shares did Kristine Johnson acquire and at what price?

Kristine Johnson acquired 6,144 shares of AtriCure common stock at a stated price of $0.00 per share. This reflects a stock-based compensation grant, not a cash purchase, and is disclosed as a Restricted Stock Award issued on May 18, 2026.

When do Kristine Johnson’s new AtriCure (ATRC) restricted shares vest?

The 6,144 AtriCure shares granted to Kristine Johnson will vest on the one-year anniversary of the May 18, 2026 grant date. Until vesting, the award remains restricted stock, aligning her compensation with company performance over the upcoming year.

What is Kristine Johnson’s AtriCure (ATRC) share ownership after this grant?

Following the restricted stock grant, Kristine Johnson directly holds 55,954 shares of AtriCure common stock. This total includes the newly awarded 6,144 restricted shares, as reflected in the updated post-transaction ownership reported in the Form 4 filing.

Under which plan was Kristine Johnson’s AtriCure (ATRC) stock grant made?

The 6,144-share grant to Kristine Johnson was issued under the AtriCure, Inc. 2023 Stock Incentive Plan. This plan provides equity-based compensation such as Restricted Stock Awards to directors and other participants to align their interests with shareholders.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 09:25 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHNSON B KRISTINE

(Last) (First) (Middle)

366 FERNDALE ROAD SOUTH

(Street)

WAYZATA MINNESOTA 55391

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AtriCure, Inc. [ ATRC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A		6,144(1)	A	$0	55,954	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person acquired these shares pursuant to a Restricted Stock Award under the AtriCure, Inc. 2023 Stock Incentive Plan. The shares will vest upon the one-year anniversary of the grant date.

Remarks:

	/s/ Allison Walker as Attorney-in-fact for B. Kristine Johnson	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)